Advertisement
UK markets open in 1 hour 47 minutes

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,184.02
    -201.85 (-1.23%)
     

  • CRUDE OIL

    84.54
    +1.81 (+2.19%)
     

  • GOLD FUTURES

    2,397.90
    -0.10 (-0.00%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    50,063.23
    +429.57 (+0.87%)
     

  • CMC Crypto 200

    1,288.62
    +403.08 (+44.37%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

FDA staff finds no new safety problems with Glaxo's asthma drug

Reuters - UK Focus

March 17 (Reuters) - GlaxoSmithKline Plc (Other OTC: GLAXF - news) 's respiratory treatment for chronic breathing problems did not show any new safety problems in treating asthma, a preliminary review by U.S. Food and Drug Administration staff found.

The review comes two days ahead of a meeting of FDA advisers to discuss the combination treatment, Breo Ellipta, and recommend whether or not it should be approved to treat asthma.

The FDA staff also said, in documents released on Tuesday, that FDA advisers would discuss the fact that the benefit of one of the components in the treatment was not demonstrated consistently. (http://1.usa.gov/1Fvj3r9) (Reporting by Vidya L Nathan and Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza)